Revolution Medicines Raises $2.2 Billion in Concurrent Public Offerings

Biotech company secures funding for late-stage oncology pipeline through stock and convertible note sales.

Apr. 17, 2026 at 9:06pm

Got story updates? Submit your updates here. ›

An extreme close-up of the intricate, industrial-looking mechanisms and components that make up the complex financial systems supporting biotech research and development, conveying a sense of power, security, and the underlying complexity of the industry.The massive capital raise by Revolution Medicines highlights the robust financial infrastructure powering the biotech industry's efforts to develop innovative cancer treatments.Redwood City Today

Revolution Medicines, a clinical-stage oncology company, announced the closing of concurrent public offerings that raised approximately $2.2 billion in gross proceeds. The offerings included the sale of 12.1 million shares of common stock at $142 per share and $500 million in 0.5% convertible senior notes due in 2033. The company plans to use the funds for general corporate purposes, including research and development, potential commercialization, and other expenses.

Why it matters

The substantial capital raise will bolster Revolution Medicines' efforts to advance its pipeline of targeted therapies for RAS-addicted cancers, a difficult-to-treat group of tumors with high unmet medical need. The funding will support the company's late-stage clinical programs as it works to bring innovative cancer treatments to market.

The details

The common stock offering included the full exercise of the underwriters' option to purchase additional shares. The convertible notes carry a 0.5% annual interest rate and have an initial conversion price of $198.80 per share, representing a 40% premium over the common stock offering price. Revolution Medicines can redeem the notes starting in May 2030 if certain conditions are met.

  • The offerings closed on April 17, 2026.
  • The convertible notes will mature on May 1, 2033.

The players

Revolution Medicines, Inc.

A late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers.

J.P. Morgan

One of the book-running managers for the note and common stock offerings.

TD Cowen

One of the book-running managers for the note and common stock offerings.

Guggenheim Securities

One of the book-running managers for the note and common stock offerings.

LifeSci Capital

The lead manager for the note and common stock offerings.

Got photos? Submit your photos here. ›

What’s next

Revolution Medicines plans to use the net proceeds from the offerings for general corporate purposes, including research and development expenses, expenses relating to the potential commercialization of one or more of its product candidates, general and administrative expenses and capital expenditures.

The takeaway

This capital raise positions Revolution Medicines to accelerate the development and potential commercialization of its promising pipeline of targeted oncology therapies, which could significantly improve outcomes for patients with difficult-to-treat RAS-addicted cancers.